CIP
ONC icon

Convergence Investment Partners’s BeOne Medicines Ltd ONC Stock Holding History

Convergence Investment Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-48
Closed -$8K – 939
2018
Q1 		$8K Buy
+48
New +$6.5K ﹤0.01% 745

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Convergence Investment Partners's ONC Position: Q2 2018 in Review

Convergence Investment Partners sold out of BeOne Medicines Ltd (ONC) in Q2 2018, closing a stake of 48 shares — an estimated $8K sold.

Convergence Investment Partners first reported a position in ONC in Q1 2018 and held it in 1 quarter. The position peaked at $8K in Q1 2018. 128 funds tracked by Wall St. Rank hold ONC as of Q2 2018.

  • Convergence Investment Partners reported no remaining BeOne Medicines Ltd position as of Q2 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 48 BeOne Medicines Ltd shares in Q2 2018, an estimated $8K.
  • Convergence Investment Partners first reported a position in BeOne Medicines Ltd in Q1 2018 and held it in 1 quarter.
  • Convergence Investment Partners's BeOne Medicines Ltd position peaked at $8K in Q1 2018.
  • 128 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.